Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer

Sung Yong Oh1, Hyuk-Chan Kwon1, Sung Hyun Kim1, Suee Lee1, Ji Hyun Lee1, Jung-Ah Hwang2, Seung Hyun Hong2, Christian A Graves3, Kevin Camphausen3, Hyo-Jin Kim1 and Yeon-Su Lee2*

Author Affiliations

1 Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea

2 Cancer Genomics Branch, Research Institute, National Cancer Center, Goyang, Gyeonggi-do, 410-769, Korea

3 Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA

For all author emails, please log on.

BMC Cancer 2013, 13:43  doi:10.1186/1471-2407-13-43

Published: 1 February 2013



The aim of this study is to evaluate the associations between vascular endothelial growth factor (VEGF) Single-nucleotide polymorphisms (SNPs) and clinical outcome in advanced gastric cancer patients treated with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX).


Genomic DNA was isolated from whole blood, and six VEGF (−2578C/A, -2489C/T, -1498 T/C, -634 G/C, +936C/T, and +1612 G/A) gene polymorphisms were analyzed by PCR. Levels of serum VEGF were measured using enzyme-linked immunoassays.


Patients with G/G genotype for VEGF -634 G/C gene polymorphism showed a lower response rate (22.2%) than those with G/C or C/C genotype (32.3%, 51.1%; P = 0.034). Patients with the VEGF -634 G/C polymorphism G/C + C/C genotype had a longer progression free survival (PFS) of 4.9 months, compared with the PFS of 3.5 months for those with the G/G (P = 0.043, log-rank test). By multivariate analysis, this G/G genotype of VEGF -634 G/C polymorphism was identified as an independent prognostic factor (Hazard ratio 1.497, P = 0.017).


Our data suggest that G/G genotype of VEGF -634 G/C polymorphism is related to the higher serum levels of VEGF, and poor clinical outcome in advanced gastric cancer patients.

VEGF; Polymorphism; Gastric cancer